share_log

Bionomics to Present at the 2024 CNS Summit

Bionomics to Present at the 2024 CNS Summit

生物體將在2024年中樞神經系統峯會上發表演講
GlobeNewswire ·  11/07 21:00

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be participating and presenting at the 15th CNS Summit being held November 10-13, 2024 at the Encore Boston Hotel in Boston, MA.

澳大利亞阿德萊德和馬薩諸塞州劍橋,2024年11月07日,(全球資訊)-- 生物諾米克有限公司(納斯達克:BNOX)(生物諾米克或公司),一家處於臨床階段的生物技術公司,正在開發新穎的、首創的、異位的離子通道調節劑,用於治療患有嚴重中樞神經系統(CNS)疾病且存在較高未滿足醫療需求的患者。今天宣佈將參加並發表在2024年11月10日至13日舉行的第15屆CNS峯會,地點位於馬薩諸塞州波士頓市的恩科爾波士頓酒店。

Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation during the Neuroscience Spotlight session taking place on Tuesday, November 12 at 1:00 p.m. ET in the Picasso ballroom.

Bionomics的總裁兼首席執行官Spyros Papapetropoulos博士將於11月12日星期二下午1:00在畢加索大廳舉行的神經科學亮點會議上發表公司演講。

Following the event, the presentation will be posted to Bionomics' website under the "Events" page of the Investors Center section.

活動結束後,演示將發佈在生物諾米克的網站上,可以在投資者中心部分的「事件」頁面查看。

FOR FURTHER INFORMATION PLEASE CONTACT:

有關信息,請聯繫:

General
Rajeev Chandra
Company Secretary
CoSec@bionomics.com.au
Investor Relations
Kevin Gardner
kgardner@lifesciadvisors.com
Investor Relations
Chris Calabrese
ccalabrese@lifesciadvisors.com
普通
Rajeev Chandra
公司秘書
CoSec@bionomics.com.au
投資者關係
Kevin Gardner
kgardner@lifesciadvisors.com
投資者關係
Chris Calabrese
ccalabrese@lifesciadvisors.com

About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other CNS conditions. Bionomics' pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need.

關於生物諾米克斯有限公司
Bionomics(納斯達克:BNOX)是一家臨床階段的生物技術公司,開發新型、潛在的首創性、變構離子通道調節劑,用於治療患有嚴重中樞神經系統(CNS)疾病且醫療需求巨大的患者。Bionomics正在推進其主力藥物候選BNC210,一種口服、專有的選擇性負變構輔助調節劑,用於社交焦慮症(SAD)的急性治療和創傷後應激障礙(PTSD)的慢性治療。除BNC210外,Bionomics與默沙東(Merck & Co., Inc.,在美國和加拿大以外地區稱爲MSD)建立了戰略合作伙伴關係,共同開發兩種早期臨床試驗藥物,用於治療阿爾茨海默氏病和其他中樞神經系統疾病的認知缺陷。Bionomics的產品線還包括針對高度醫療需求的CNS疾病開發的靶向Kv3.1/3.2和Nav1.7/1.8離子通道的臨床前資產。

Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the closing of each tranche of the Company's private placement financing, the achievement of certain milestones for the various tranches, the timely funding to the Company by each investor in the private placement, the timing, size and expectation of the closing of the private placement; and expectations regarding market conditions, the satisfaction of customary closing conditions related to the private placement and the anticipated use of proceeds therefrom; and the Company's expectation that its current cash, cash equivalents, and marketable securities will fund our operations into the third quarter of 2025. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business and other risks described in the Company's filings with the Securities and Exchange Commission (SEC), including, but not limited to, the Company's Annual Report on Form 20-F filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics' filings with the SEC, copies of which are available from the SEC's website (www.sec.gov) and on Bionomics' website () under the heading "Investor Center." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

前瞻性聲明
生物諾米克斯警告說,包含在本新聞稿中的非歷史事實陳述屬於前瞻性陳述。意圖識別前瞻性陳述的詞語包括"may"、"could"、"will"、"would"、"should"、"expect"、"plan"、"anticipate"、"believe"、"estimate"、"intend"、"predict"、"seek"、"contemplate"、"potential"、"continue"或"project",或這些術語的否定形式或其他類似術語。前瞻性陳述基於我們目前的信念和期望,包括但不限於:本公司私募股權融資的每個部分的結束,各部分的某些里程碑的實現,各個投資者向本私募股權融資中的公司及時提供資金,私募股權融資的時機、規模和預期的收盤價,市場狀況、有關私募股權融資的慣常收盤條件的滿足以及預期的中期財務狀況。包含前瞻性陳述不應被視爲生物諾米克斯的任何計劃將被實現的陳述。由於公司業務內在的風險和不確定性以及包括但不限於公司在美國證券交易委員會(SEC)提交的年度報告20-F和其他報告中描述的其他風險,所以實際結果可能與本新聞稿中所設定的目標有所不同。投資者應當不需要把所有的期望放在這些前瞻性陳述上,這些陳述僅在發佈日期作出,生物諾米克斯不必就任何或所有本新聞稿內容可能採取或不採取的行動承擔任何責任。更多關於這些及其他風險、不確定性和其他因素的信息,均包括在SEC的文件、SEC網站(www.sec.gov)和Bionomics網站()投資人中心下的副標題中。所有的前瞻性陳述都在這個警告聲明下獲得了認證。這個警告是根據1995年《私人執法改革法》第 21 條的安全港規定發佈的。生物諾米克斯明確否認對於基於本新聞稿的所有內容所採取或未採取的行動承擔任何責任。


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論